A multicenter, randomized, double blinded, parallel-group, placebo controlled study to assess the efficacy and safety of skeletal muscle-derived cell implantation in female patients with stress urinary incontinence
Phase of Trial: Phase III
Latest Information Update: 21 Jun 2019
Price : $35 *
At a glance
- Drugs ICES 13 (Primary)
- Indications Stress incontinence
- Focus Registrational; Therapeutic Use
- Acronyms Innovation
- Sponsors Innovacell Biotechnologie GmbH
- 12 Dec 2015 Status changed from recruiting to completed, according to European Clinical Trials Database
- 28 Sep 2015 EudraCT reports planned patient no as 369 in Czech Republic.
- 21 Apr 2015 New source identified and integrated: European Clinical Trials Database record.